Thelansis

Advanced or Metastatic Soft Tissue Sarcomas (STS) Market Outlook Thelansis’s “Advanced or Metastatic Soft Tissue Sarcomas (STS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Soft Tissue Sarcomas (STS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient s...

  Advanced or Metastatic Soft Tissue Sarcomas (STS) Market Outlook Thelansis’s “Advanced or Metastatic Soft Tissue Sarcomas (STS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Soft Tissue Sarcomas (STS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Advanced or Metastatic Soft Tissue Sarcomas (STS) Overview Soft tissue sarcomas (STS), aggressive mesenchymal-origin tumors, represent 1% of all adult malignancies, with the World Health Organization recognizing over 50 distinct histological subtypes. Currently, the primary treatment strategy for localized STS involves surgery, optionally supplemented with ...

  Soft tissue sarcomas (STS), aggressive mesenchymal-origin tumors, represent 1% of all adult malignancies, with the World Health Organization recognizing over 50 distinct histological subtypes. Currently, the primary treatment strategy for localized STS involves surgery, optionally supplemented with perioperative chemotherapy. For patients with advanced or metastatic STS, the first-line treatment typically consists of palliative anthracycline-based chemotherapy administered either alone or in combination with ifosfamide. This applies to most STS subtypes. STS is known for their aggressive nature and propensity to infiltrate deep tissues. They exhibit a high recurrence rate of 35%, and in 16% of all cases, metastasis is already present at the time of diagnosis, predominantly affecting the lungs. The Overall Survival (OS) for patients with advanced metastatic STS is approximately 12 months. However, recent studies involving newer drugs have extended OS to 18 months. Interestingly,...